Navigation Links
New Study Results Published in the New England Journal of Medicine Show Dabigatran Etexilate Mesylate Reduces the Risk of Recurrent Venous Thromboembolism
Date:2/20/2013

RIDGEFIELD, Conn., Feb. 20, 2013 /PRNewswire/ -- New findings from two double-blind, randomized trials, RE-MEDYSM and RE-SONATE®, show that dabigatran 150 mg twice daily reduces the risk of recurrent venous thromboembolism (VTE)*. The results were published today in the New England Journal of Medicine.

VTE is the third most common cardiovascular disorder after heart disease and stroke, and consists of two related conditions caused by blood clots: deep vein thrombosis (DVT) and pulmonary embolism (PE). DVT is when a blood clot develops in the deep veins of the leg or pelvis. The clot, or part of it, can break off from the site where it formed and travel through the veins (embolism). A PE can occur if the clot lodges in the arteries of the lungs.

There are an estimated 900,000 VTE events per year in the U.S., approximately one-third of which result in death from PE. Further, roughly one-third of people with VTE will have a recurrence within 10 years. The standard of care for patients with VTE is anticoagulation.

RE-MEDY demonstrated that treatment with dabigatran 150 mg twice daily was non-inferior to warfarin (p=0.01) in preventing recurrent VTE, including VTE-related death. RE-SONATE demonstrated dabigatran was superior to placebo for the prevention of first recurrent or fatal VTE with a risk reduction of 92 percent during the treatment period (p<0.001). Lower event rates were reported across all secondary efficacy endpoints for dabigatran over placebo.

"Patients who suffer one VTE event are at increased risk of suffering another, with the risk accumulating over time," said Sam Schulman , M.D., Ph.D., FRCPC(C), lead study author and professor, Department of Medicine, McMaster University, Ontario, Canada. "We are encouraged to see that the RE-MEDY and RE-SONATE trials met their endpoints and we will continue to study the safety, efficacy and p
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
2. Study Showed Patients Treated With The miraDry© System Experienced 82 Percent Sweat Reduction On Average
3. Asubio Initiates Landmark Clinical Study in Spinal Cord Injury
4. New Veridex Alliance Drives Study Of Circulating Tumor Cells In Men With Metastatic Prostate Cancer
5. Shingles Vaccine is Safe, According to New Study
6. Structural Trends to Profoundly Change Life Sciences Industry, Genpact Study Shows
7. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
8. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
9. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
10. Accuray Launches First Study to Compare CyberKnife® SBRT to Surgery and IMRT for Treatment of Early-Stage Prostate Cancer
11. Interim results of VITOBA™ (VImpaT® added to One Baseline AED) Study Presented at the 64th Annual Meeting of the American Academy of Neurology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2015)... LONDRES, August 29, 2015 ... para los sistemas de imagen por Ultrasonidos   ... tiempos de examen rápidos y un flujo de trabajo ... diagnóstica en el proceso de detección de Cardiopatías   ... ha anunciado hoy el lanzamiento europeo de HeartModel ...
(Date:8/28/2015)... 28, 2015 Research ... addition of the "Investigation Report on China,s ... Originally discovered by Welfide (Mitsubishi Tanabe ... Ltd) as an inflammatory drug, pranoprofen was later ... Ltd under the trade name of pranopulin for ...
(Date:8/28/2015)... Ill. , Aug. 28, 2015 ... Companies, Inc. (Nasdaq: PDCO ), is now ... previously announced acquisition of Patterson Medical by Madison ... will retain its name for a transition period ... of rehabilitation and sports medicine products.  With the ...
Breaking Medicine Technology:Philips presenta HeartModel A.I en el Congreso ESC 2015 2Philips presenta HeartModel A.I en el Congreso ESC 2015 3Philips presenta HeartModel A.I en el Congreso ESC 2015 4Philips presenta HeartModel A.I en el Congreso ESC 2015 5Investigation Report on China's Pranoprofen Market, 2010-2019 2Patterson Medical Positioned for Continued Growth as a Newly Independent Company 2Patterson Medical Positioned for Continued Growth as a Newly Independent Company 3
... NEW YORK, June 23, 2011 OTC ... that operates the world,s largest electronic marketplace for ... Radient Pharmaceuticals Corporation (OTCQX: RXPC), the ... cancer blood test kit, has qualified to trade ...
...   Jubilant Biosys Ltd., Bengaluru, based ... another,successful delivery of an early stage milestone in the ... ago in the Neuroscience,therapeutic area, has now expanded to ... a steady stream of,preclinical outcomes to AstraZeneca, by Jubilant. ...
Cached Medicine Technology:Radient Pharmaceuticals Corporation Joins OTCQX 2Radient Pharmaceuticals Corporation Joins OTCQX 3Jubilant and AstraZeneca Announce Successful Delivery of Early Milestones in Drug Discovery 2
(Date:8/30/2015)... ... August 30, 2015 , ... InHealth Media ... the new Global Communications Director for InHealth Media. Mr. Spector comes with ... last 16 years doing on-air television, producing shows, on air-radio and media relations. ...
(Date:8/30/2015)... ... August 30, 2015 , ... Nutritional ... from Administrative assistant to Executive Assistant to CEO Mitch Gould for Nutritional Products ... focused on your goals. Kathleen graduated from Florida State University with a ...
(Date:8/29/2015)... ... August 30, 2015 , ... ... 2015 — 1:30 p.m. – 3:00 p.m. EDT, http://www.fdanews.com/electronicinformedconsent , The ... simple digital handwritten signature. , Clinical trial sites can now use ...
(Date:8/29/2015)... Raleigh, NC (PRWEB) , ... August 29, 2015 ... ... about how mesothelioma develops, may extend and improve the lives of patients, according ... its website. Click here to read the full article. , The ...
(Date:8/29/2015)... ... August 29, 2015 , ... ProDrop Particles includes over 40 particle backdrops ... seconds of unique footage that users can shrink and stretch in the Final Cut ... Users can customize color, brightness, scale, speed, range, and flare attributes with intuitive controls ...
Breaking Medicine News(10 mins):Health News:InHealth Media Appoints New Global Communications Director 2Health News:NPI Appoints New Executive Assistant To CEO 2Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 2Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 3Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 4Health News:Top Mesothelioma Researchers Highlight Targeted Therapies in New Report, According to Surviving Mesothelioma 2Health News:FCPX Effects Developer, Pixel Film Studios, Releases ProDrop Particles. 2
... Gold Standard Drug Through 2016, According ... to a New Report from Decision Resources, WALTHAM, ... research and advisory firms focusing on pharmaceutical and,healthcare issues, finds ... lower discontinuation rate than that of Abbott,s,Niaspan ER (extended release) ...
... Quarter Results to be Reported Wednesday, August 6th After Market ... ... The Providence Service,Corporation (Nasdaq: PRSC ) today announced that primarily ... that,fund the services the Company provides, diluted earnings per share for the,second ...
... Calif., July 29 Genomic Health,Inc. (Nasdaq: GHDX ... conference,call and webcast on Tuesday, August 5, 2008 at ... financial results. The call and webcast,will follow the release ... Conference Call Details, To access the live conference ...
... Showed Reduction in Fall Risk, MELVILLE, N.Y., July ... program from Gentiva Health Services,Inc., is reducing the risk ... of older Americans, according to a new,national survey of ... The year-long survey comprising 10,023 patients revealed these ...
... any gaps in coverage or inadequate protection , ... ... http://www.combinedinsurance.com/ [Combined Insurance], a leading provider of supplemental insurance, ... sponsored by SWWAN® (Single Working Women,s Affiliate Network), marks an ...
... is the talk of the industry. Painless, less intrusive and more ... http://www.austinsmiles.com/dental-gallery-01.html [smile makeover __title__ Dr. McCarty Smile Makeover Gallery] in ... ... (PRWEB) July 29, 2008 -- Dr. Michael McCarty of http://www.austinsmiles.com ...
Cached Medicine News:Health News:A High-Density Lipoprotein Raising Drug That Has a Lower Discontinuation Rate Than That of Extended Release Niaspan Would Earn a 20 Percent Patient Share in the Dyslipidemia Drug Market 2Health News:Providence Service Corporation Sees Budget Clarity Improving Toward Year End With Budget Issues Impacting Second Quarter and Balance of 2008 2Health News:Providence Service Corporation Sees Budget Clarity Improving Toward Year End With Budget Issues Impacting Second Quarter and Balance of 2008 3Health News:Providence Service Corporation Sees Budget Clarity Improving Toward Year End With Budget Issues Impacting Second Quarter and Balance of 2008 4Health News:Providence Service Corporation Sees Budget Clarity Improving Toward Year End With Budget Issues Impacting Second Quarter and Balance of 2008 5Health News:Genomic Health to Announce Second Quarter 2008 Financial Results and Host Conference Call on Tuesday, August 5, 2008 2Health News:Gentiva Safe Strides(R) Home Balance Therapy Program is Reducing Risk of Dangerous Falls and Relieving Pain for Thousands of Older Americans 2Health News:Gentiva Safe Strides(R) Home Balance Therapy Program is Reducing Risk of Dangerous Falls and Relieving Pain for Thousands of Older Americans 3Health News:Gentiva Safe Strides(R) Home Balance Therapy Program is Reducing Risk of Dangerous Falls and Relieving Pain for Thousands of Older Americans 4Health News:Gentiva Safe Strides(R) Home Balance Therapy Program is Reducing Risk of Dangerous Falls and Relieving Pain for Thousands of Older Americans 5Health News:Combined Insurance Reports that Single Working Women's Week is a Good Time for Annual Review of Insurance Coverage 2Health News:Combined Insurance Reports that Single Working Women's Week is a Good Time for Annual Review of Insurance Coverage 3Health News:Combined Insurance Reports that Single Working Women's Week is a Good Time for Annual Review of Insurance Coverage 4Health News:Combined Insurance Reports that Single Working Women's Week is a Good Time for Annual Review of Insurance Coverage 5Health News:Will Lumineers Replace Traditional Veneers? 2Health News:Will Lumineers Replace Traditional Veneers? 3
Provides a combination of concentrated cold / hot and compression for the knee...
Provides extended cold therapy for acute, chronic, or post-surgical applications. Cryotherapy can reduce pain, swelling and speed recovery....
Provides a combination of concentrated cold / hot and compression for the back...
Provides compression, support, immobilization for the knee in addition to cold / hot therapy...
Medicine Products: